CROSSJECT (EPA:ALCJ) | Finanzwire

Basculer en Français

11265	Companies
250264	Keywords
178763	Articles
136120	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 06/04/2025 at 20:21, 1 year 4 months ago

Launch of a capital increase with preferential subscription rights for nearly 5 million euros
CROSSJECT announces capital increase with preferential subscription rights totaling nearly 5 million euros. Existing shareholders and Vatel Capital commit to subscribe 76.4% of the amount. Subscription price set at 1.40 euros. Subscription period from June 12 to June 20, 2025

Capital Increase Subscription Period Preferential Subscription Rights Crossject Vatel Capital
BRIEF

published on 06/03/2025 at 07:35, 1 year 5 months ago

Maxim Group Recommends CROSSJECT with €4.00 Target Price

Buy Recommendation Crossject ZEPIZURE® Needle-free Auto-injector Maxim Group
PRESS RELEASE

published on 06/03/2025 at 07:30, 1 year 5 months ago

Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
Maxim Group initiates coverage of CROSSJECT with BUY recommendation and €4.00 target price. CROSSJECT, a specialty pharma company, looks forward to positive developments with FDA and pipeline

FDA Buy Recommendation Specialty Pharma Crossject Maxim Group
BRIEF

published on 05/27/2025 at 07:35, 1 year 5 months ago

CROSSJECT optimizes its production with the ZENEO® Nest

CDMO Funding Production Crossject ZENEO® Nest
BRIEF

published on 05/20/2025 at 07:35, 1 year 5 months ago

CROSSJECT Plans €5 Million Capital Increase to Boost EUA Approval Activities

Capital Increase Crossject ZEPIZURE® Gemmes Venture EUA Approval
PRESS RELEASE

published on 05/20/2025 at 07:30, 1 year 5 months ago

CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
CROSSJECT plans 5 million euros capital increase, may increase to 5.8 million euros, Gemmes Venture to guarantee 75% of initial amount, Heights Capital Management supports offer

Capital Increase Crossject Gemmes Venture Heights Capital Management EUA Approval
BRIEF

published on 05/07/2025 at 07:35, 1 year 5 months ago

CROSSJECT: Progress in the EUA authorization application for ZEPIZURE®

FDA USA ZEPIZURE® BARDA CHEMPACK
BRIEF

published on 03/27/2025 at 07:35, 1 year 7 months ago

CROSSJECT Publishes 2024 Financial Results

Financial Results Cash Position Partnerships FDA Filing ZEPIZURE®
PRESS RELEASE

published on 03/27/2025 at 07:30, 1 year 7 months ago

CROSSJECT reports financial results for 2024
CROSSJECT reports financial results for 2024 and progress in clinical and regulatory activities, recruitment of COO, and increased cash position. Key achievements and future plans outlined

Financial Results Cash Position Clinical Activities Crossject Regulatory Development
BRIEF

published on 03/25/2025 at 07:35, 1 year 7 months ago

Strategic partnership between CROSSJECT and ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Adrenal Insufficiency

Accesswire

Published on 11/03/2026 at 15:30, 22 minutes ago

Murchison Minerals Announces $1 Million Non-Brokered Private Placement
Published on 11/03/2026 at 15:05, 47 minutes ago

ACCESS Newswire to Host Third Quarter Earnings Conference Call on November 10, 2026
Published on 11/03/2026 at 14:31, 1 hour 21 minutes ago

First Breach Adds Inspection Equipment and Secures Strategic Supply Agreements to Support Ammunition Production
Published on 11/03/2026 at 14:00, 1 hour 52 minutes ago

Global Education Communities Corp. Provides Corporate Update on Student Housing Portfolio and Development Projects
Published on 11/03/2026 at 13:48, 2 hours 4 minutes ago

EonX Announces Strategic Technology Partnership with Metcash, Australia's Leading Wholesaler and Service Provider to Independent Business Operators

View all ACCESSWIRE

EQS Group

Published on 11/03/2026 at 15:39, 12 minutes ago

Change to Director Responsibilities
Published on 11/03/2026 at 15:37, 14 minutes ago

Alzchem Group AG focuses on continuity in sales: Martina Spitzer’s Management Board contract extended early through 2029
Published on 11/03/2026 at 15:35, 16 minutes ago

Holding(s) in Company
Published on 11/03/2026 at 15:05, 46 minutes ago

Orion Innovation Unveils the Next Generation of OI NEBULA™, Its Suite of Agentic SDLC Platforms
Published on 11/03/2026 at 15:00, 52 minutes ago

ZF Europe Finance B.V. hereby announce the results of the Tender Offer.

Les Echos

Published on 11/03/2026 at 07:00, 8 hours 52 minutes ago

bioMérieux – Third-Quarter 2026 Business Review
Published on 11/02/2026 at 21:08, 18 hours 43 minutes ago

GROUPE SFPI LIQUIDIDY CONTRAT H1 2026
Published on 11/02/2026 at 18:30, 21 hours 22 minutes ago

Disclosure of transactions in own shares from October 26 to October 30, 2026
Published on 11/02/2026 at 18:17, 21 hours 34 minutes ago

Reporting on share buyback transactions carried out between October 28 and October 29, 2026
Published on 11/02/2026 at 18:00, 21 hours 52 minutes ago

Covivio - Information on total number of voting rights and share capital

View all LES ECHOS COMFI WIRE